Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL389036 | 1.00 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL30475600 | 1.00 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL8007402 | 0.92 | PPARG (0.86) | PPARGPPARA | |
| SCHEMBL7815152 | 0.92 | PPARG (0.84) | PPARGPPARA | |
| SCHEMBL7997939 | 0.92 | PPARG (0.84) | PPARGPPARA | |
| SCHEMBL9267167 | 0.89 | PPARG (0.86) | PPARGPPARA | |
| SCHEMBL10211510 | 0.89 | PPARG (0.86) | PPARGPPARA | |
| SCHEMBL13588984 | 0.89 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL7822831 | 0.89 | PPARG (1.00) | PPARGPPARA | |
| SCHEMBL7823360 | 0.89 | PPARG (0.85) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 344 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743083-A1 | METHODS OF TREATING FIBROTIC LIVER DISEASES OR CONDITIONS WITH INDEGLITAZAR | Pleiogenix Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| WO-2026102082-A1 | ALKYLPHENYL SUBSTITUTED COMPOUNDS, COMPOSITIONS AND METHODS OF USE | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20260130872-A1 | Substituted Bicyclic Compounds, Compositions and Methods of Use | DEEP APPLE THERAPEUTICS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026088071-A1 | SUBSTITUTED FUSED HETEROARYL LACTAM COMPOUNDS | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4076459-B1 | PRMT5 INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | PFIZER INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-12595248-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-12595262-B2 | PRMT5 inhibitors | MERCK SHARP & DOHME LLC (US) | 2026-04-07 | — | — | US | disclosed |
| US-6444816-B1 | DIETETICS, ANTICHOLESTEROL AGENTS, ANTIDIABETIC AGENTS | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-09-03 | — | — | US | disclosed |
| WO-2002062799-A1 | ARYL SUBSTITUTED ALKYLCARBOXYLIC ACIDS AS HYPOCHOLESTEROLEMIC AGENTS | DR. REDDY'S LABORATORIES LTD. (IN) | 2002-08-15 | — | — | WO | disclosed |
| US-20020103215-A1 | New monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. | 2002-08-01 | — | — | US | disclosed |
| US-20020082258-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2002-06-27 | — | — | US | disclosed |
| US-6369067-B1 | Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S RESEARCH FOUNDATION (IN) | 2002-04-09 | — | — | US | disclosed |
| US-6265401-B1 | ANTIDIABETIC AGENTS | REDDY-CHEMINOR, INC. | 2001-07-24 | — | — | US | disclosed |
| US-6166049-A | Use of an antagonist of PPARα and PPARγ for the treatment of syndrome X | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-12-26 | — | — | US | disclosed |
| EP-0879053-A1 | USE OF AN ANTAGONIST OF PPAR-ALPHA AND PPAR-GAMMA FOR THE TREATMENT OF SYNDROM X | SMITHKLINE BEECHAM PLC (GB) | 1998-11-25 | — | — | EP | disclosed |
| WO-1997025042-A1 | USE OF AN AGONIST OF PPAR-ALPHA AND PPAR-GAMMA FOR THE TREATMENT OF SYNDROM X | SMITHKLINE BEECHAM P.L.C. (GB) | 1997-07-17 | — | — | WO | disclosed |
| WO-1996004261-A1 | BENZOXAZOLES AND PRYRIDINE DERIVATIVES USEFUL IN THE TREATMENT OF THE TYPE II DIABETES | SMITHKLINE BEECHAM PLC (GB) | 1996-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260130872-A1 | Substituted Bicyclic Compounds, Compositions and Methods of Use | GIPR, GLP1R, SIGMAR1 | PPARG 790/4885PPARA 2483/4885 |
| US-12595248-B2 | PRMT5 inhibitors | PRMT5, PRMT1, PRMT6 | PPARG 4438/4885PPARA 4662/4885 |
| US-12595262-B2 | PRMT5 inhibitors | PRMT1, PRMT5, CARM1 | PPARG 3888/4885PPARA 3780/4885 |
| US-20020082258-A1 | Novel bicyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them | SLC5A1, CYP11B1, CYP4A11 | PPARG 618/4885PPARA 884/4885 |
| US-20260132119-A1 | Alkylphenyl Substituted Compounds, Compositions and Methods of Use | GIPR, MC2R, GRPR | PPARG 473/4885PPARA 1636/4885 |
| US-20260132164-A1 | PNU ANTHRACYCLINE DERIVATIVES AND METHODS OF USE THEREOF | TOP1, NCL, NOLC1 | PPARG 3339/4885PPARA 2387/4885 |
| US-12611401-B2 | Combinations comprising benzodioxol as GLP-1R agonists for use in the treatment of NASH/NAFLD and related diseases | GLP1R, GCKR, GPR119 | PPARG 12/4885PPARA 39/4885 |
| US-20020103215-A1 | New monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them | CYP11B1, CYP46A1, CYP27A1 | PPARG 133/4885PPARA 176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.